Tempus AI
TEM · NASDAQ · Healthcare
$77.84
$2.44 (-3.14%) today
Market Cap
$9.40B
24h Volume
$724.2M
P/E Ratio
0.0
52w High
$103.25
52w Low
$41.55
Est. AI Revenue
85%
7-Day Sparkline (Static)
Company facts
Performance
About Tempus AI
Tempus AI is a healthcare technology company built around data. It sells AI driven genomic sequencing to oncologists, licenses its clinical and molecular data library to pharmaceutical companies, and provides tools that match patients to therapies, earning revenue across diagnostics and data services.
Its products include the Tempus ONE AI platform, next generation sequencing with AI analysis, clinical data intelligence for research, and AI therapy matching that connects patients with treatments and trials. It trains multimodal foundation models on that library, which the company describes as the world's largest of its kind.
Founded in 2015 and headquartered in Chicago, Illinois, Tempus employs about 3,800 people under founder and CEO Eric Lefkofsky, and trades on the NASDAQ.
Tempus AI in the AI buildout
Tempus sits in the AI Healthcare and Foundation Models layers of the buildout. Its entire business is built on monetizing a clinical and molecular data library with AI: sequencing that feeds the library, multimodal foundation models trained on it, and licensing that sells access to both. There is no separate legacy business underneath, so the AI thesis is essentially the whole story. Supercycle scores its AI exposure at 88 out of 100, near the pure play end of the leaderboard.
TEM is tracked in AI Healthcare and Foundation Models, rated Core on the AI Exposure leaderboard.
By the numbers
52-week range
TEM trades at $77.84, 59% of the way up its 52-week range of $41.55 to $103.25.
Market cap
Market capitalization is $9.40B, with an AI Exposure Score of 88 out of 100.
Market data as of the close on . Prices are end of day, not live.
Frequently asked questions
What does Tempus AI do?
Tempus sells AI driven genomic sequencing to oncologists, licenses its clinical and molecular data library to pharma, and provides AI tools that match patients to therapies and trials.
How is Tempus AI exposed to AI?
Almost entirely. The company is built on monetizing its clinical data library with AI, making the buildout thesis essentially the whole story. Supercycle scores its exposure at 88 out of 100.
What are Tempus AI's main products?
The Tempus ONE AI platform, next generation sequencing with AI analysis, clinical data intelligence for research, and AI therapy matching tools.
Who leads Tempus AI and where is it based?
Founder Eric Lefkofsky is CEO. Tempus is headquartered in Chicago, Illinois, was founded in 2015, employs about 3,800 people, and trades on the NASDAQ.
Is TEM a pure play AI stock?
Very close to it. AI driven diagnostics and data licensing are the entire business, and its Supercycle AI Exposure Score of 88 out of 100 places it near the top of the leaderboard.
Profile written 2026-08, updated as the business changes. Editorial content, not investment advice.
Related reading
- How to track congress stock trades, step by step · Congress must disclose every stock trade over $1,000 within 45 days. Where the filings live, how to read one line by line, and what the ranges and dates hide.